- Home
- CRIS vs CMMB Comparison
CRIS vs CMMB Comparison
Compare CRIS & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRIS
- CMMB
- Stock Information
- Founded
- CRIS 2000
- CMMB 2004
- Country
- CRIS United States
- CMMB Israel
- Employees
- CRIS N/A
- CMMB N/A
- Industry
- CRIS Biotechnology: Biological Products (No Diagnostic Substances)
- CMMB Biotechnology: Pharmaceutical Preparations
- Sector
- CRIS Health Care
- CMMB Health Care
- Exchange
- CRIS Nasdaq
- CMMB Nasdaq
- Market Cap
- CRIS 31.2M
- CMMB 27.0M
- IPO Year
- CRIS 2000
- CMMB N/A
- Fundamental
- Price
- CRIS $3.99
- CMMB $1.68
- Analyst Decision
- CRIS Strong Buy
- CMMB Strong Buy
- Analyst Count
- CRIS 3
- CMMB 3
- Target Price
- CRIS $23.00
- CMMB $7.33
- AVG Volume (30 Days)
- CRIS 72.6K
- CMMB 115.6K
- Earning Date
- CRIS 11-14-2024
- CMMB 11-14-2024
- Dividend Yield
- CRIS N/A
- CMMB N/A
- EPS Growth
- CRIS N/A
- CMMB N/A
- EPS
- CRIS N/A
- CMMB N/A
- Revenue
- CRIS $10,259,000.00
- CMMB N/A
- Revenue This Year
- CRIS N/A
- CMMB N/A
- Revenue Next Year
- CRIS N/A
- CMMB N/A
- P/E Ratio
- CRIS N/A
- CMMB N/A
- Revenue Growth
- CRIS 0.44
- CMMB N/A
- 52 Week Low
- CRIS $3.51
- CMMB $0.42
- 52 Week High
- CRIS $17.49
- CMMB $2.55
- Technical
- Relative Strength Index (RSI)
- CRIS 31.48
- CMMB 57.63
- Support Level
- CRIS $3.70
- CMMB $1.56
- Resistance Level
- CRIS $4.55
- CMMB $1.90
- Average True Range (ATR)
- CRIS 0.45
- CMMB 0.15
- MACD
- CRIS -0.04
- CMMB 0.04
- Stochastic Oscillator
- CRIS 32.21
- CMMB 59.09
About CRIS Curis Inc.
Curis Inc is a biotechnology company that develops and commercializes innovative drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, advanced solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101 treating rare fibrotic conditions.